Notice of Completion of Acquisition of Treasury Shares  
(Acquisition of Treasury Shares pursuant to the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Japan, June 23, 2008 – Astellas Pharma Inc. (“the Company,” headquarters: Tokyo, President and CEO: Masafumi Nogimori) announced that it completed acquisition of its Treasury Shares, which was resolved by its Board of Directors on May 13, 2008, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Class of shares acquired: Common stock of the Company
2. Total number of shares acquired: 9,085,500 shares
3. Total value of acquisition: ¥39,999,735,000

(Reference)

Resolution of the Board of Directors on May 13, 2008

(1) Class of shares to be acquired: Common stock of the Company
(2) Total number of shares to be acquired: 9.1 million shares (Maximum)  
(The percentage compared to the total number of issued shares (excluding Treasury Shares): 1.82%)
(3) Aggregate amount of acquisition cost: 40 billion yen (Maximum)
(4) Period of acquisition: From May 15, 2008 to June 20, 2008

Contacts for inquiries or additional information

Astellas Pharma Inc.  
Corporate Communications  
Tel: +81-3-3244-3201  Fax: +81-3-5201-7473  
http://www.astellas.com